Long-acting growth hormone analogue
Somapacitan
Brand names: Sogroya
Adult dose
Dose: Adult GH deficiency: 1.5mg SC once weekly initial, titrate per IGF-1
Route: SC
Frequency: weekly
Clinical pearls
- Adult GH deficiency — once-weekly alternative to daily somatropin
- Specialist endocrine
Contraindications
- Active malignancy
- Diabetic retinopathy (uncontrolled)
- Acute critical illness
- Pregnancy
- Hypersensitivity
Side effects
- Headache
- Injection-site reactions
- Peripheral oedema
- Hyperglycaemia
- Arthralgia
- Carpal tunnel syndrome
Interactions
- Insulin/oral antidiabetics
- Corticosteroids (monitor cortisol)
- Hormonal therapies
Monitoring
- IGF-1
- Glucose
- TFTs
- Adrenal function
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/somapacitan/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Corrected QT Interval (Bazett) · ECG
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Estimated Fetal Weight (Hadlock) · Fetal Growth
- Salter-Harris Classification of Physeal Fractures · Paediatric Fractures
- Tanner Staging (Sexual Maturity Rating) · Growth & Development
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016